Past events

  • WEBINAR 92nd ICREA COLLOQUIUM - The impact of the Covid19 pandemic: economic, social, medical and scientific aspects


    Speakers: ICREA Research Professors Massimo Motta, from Universitat Pompeu Fabra (UPF), and Christian Brander, from Institut de Recerca de la Sida - IrsiCaixa (IrsiCaixa)


    When: 15th of December 2020, 18:00h






    Dr. Christian Brander will discuss briefly the immunological hallmarks of CoV2 infection, the course of the epidemic and review the current status of vaccine development, with a special focus on fast track clinical trial procedure.


    On the other hand, Dr. Massimo Motta will explore the short-run and (possible) long-run effects of the covid crisis, from a microeconomic perspective.

  • Workshop 'El paleoclima de Barcelona – Repensar el passat per encarar el futur’


    ICREA Research Professors Antoni Rosell (ICTA-UAB) and Francesc Burjachs (IPHES) will participate in the workshop ‘El paleoclima de Barcelona – Repensar el passat per encarar el futur’.


    The workshop will be held at MUHBA Casa de l’Aigua (Torrent de la Perera, s/n, 08033 Barcelona) on the 28th of November from 9:45 h to 13:30 h.


    For detailed information on this event please click here.

  • Workshop 'Què és l'envelliment? Noves maneres d’entendre’l'


    ICREA Research Professor Manuel Serrano (IRB Barcelona) and Professor Josep Ramoneda co-organize the workshop ‘Què és l’envelliment? Noves maneres d’entendre’l’. Two other ICREA Research Professors, Santiago Zabala (UPF) and Núria Montserrat (IBEC), will participate as guests in the event.


    The workshop will be held at Palau Macaya (Passeig de Sant Joan, 108, Barcelona) in four sessions on the 17th and the 18th of November from 17:00 h to 20:30 h.


    For detailed information on this event please click here.

  • WEBINAR 91st ICREA COLLOQUIUM - Chasing targets for cancer therapy: from basic research to spin-off


    Speakers: ICREA Research Professors Laura Soucek, from Vall d’Hebron Institut d'Oncologia (VHIO), and Angel Rodriguez Nebreda, from the Institut de Recerca Biomèdica (IRB Barcelona)


    When: 27th of October 2020, 18:00h






    Dr. Nebreda and Dr. Soucek will tell us about their challenges and efforts in drugging unconventional targets in cancer:


    Dr. Nebreda will focus on p38a, a broadly expressed protein kinase that is activated by many extracellular stimuli and controls multiple cellular responses. Although p38a is not an oncogene, cancer cells often rely on this signaling pathway for proliferation and to survive chemotherapy drugs. In addition, p38a signaling mediates the communication between non-cancer cells of the tumor microenvironment and cancer cells, which contributes to tumor progression. Dr. Nebreda will describe his studies related to p38a functions in different tumor cell types to rationalize the use of p38a inhibitors for cancer therapy.


    On the other hand, Dr. Soucek will tell us about MYC, one of the most wanted targets for therapeutic intervention in cancer, having a  key role in driving and maintaining most, if not all, human tumors. Despite this indisputable therapeutic opportunity, MYC has long been perceived as “undruggable” for its intrinsically disordered nature and fear of catastrophic side effects in normal tissues. Indeed, to date, there is still no MYC inhibitor in the clinic. Dr. Soucek’s research has recently resulted in the creation of Peptomyc S.L., a spin off company of VHIO and ICREA. Peptomyc will start clinical trials testing a first-in-class MYC inhibitor in cancer patients in early 2021.